Efficacité de l’erlotinib en réanimation chez les patients présentant un cancer bronchique non à petites cellules avec une mutation de l’EGFR

Dewolf, Maxime; Dayen, C.; Garoute, C.; Khamis, Warda; Fourrier, M.; Rousselle, F; Sadki, M.; Meunier, Florence; Suguenot, R.; Lecuyer, E.; Bentayeb, H.; Douadi, Y.; Berna, Pascal

doi:10.1016/j.pneumo.2017.03.004

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is limited evidence suggesting the use of TKI in EGFR-mutant lung cancer patients who suffer from respiratory failure and need ICU admission. A few case series exist regarding the use of targeted therapy for patients with NSCLC in the ICU [6,[15][16][17][18][19]. Besides targeted therapies, immune checkpoint inhibitors have also refined the paradigm of lung cancer treatment in the past decade, especially in patients with high programmed death-ligand 1 (PD-L1) expression [20,21].…”

Section: Introductionmentioning

confidence: 99%

Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation

et al. 2021

View full text Add to dashboard Cite

Background: Respiratory failure requiring mechanical ventilation is the major reason for lung cancer patients being admitted to the intensive care unit (ICU). Though molecular targeted therapies, especially epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), have largely improved the survival of oncogene-driven lung cancer patients, few studies have focused on the performance of TKI in such settings. Materials and Methods: This was a retrospective cohort study enrolling non-small cell lung cancer (NSCLC) patients who harbored sensitizing EGFR mutation and had received EGFR-TKIs as first-line cancer therapy in the ICU with mechanical ventilator use. The primary outcome was the 28-day ICU survival rate, and secondary outcomes were the rate of successful weaning from the ventilator and overall survival. Results: A total of 35 patients were included. The 28-day ICU survival rate was 77%, and the median overall survival was 67 days. Multivariate logistic regression revealed that shock status was associated with a lower 28-day ICU survival rate independently (odds ratio (OR) 0.017, 95% confidence interval (CI), 0.000–0.629, p = 0.027), and that L858R mutation (L858R compared with exon 19 deletion, OR, 0.014, 95% CI 0.000–0.450, p = 0.016) and comorbidities of diabetes mellitus (DM) (OR, 0.032, 95% CI, 0.000–0.416, p = 0.014)) were independently predictive of weaning failure. The successful weaning rate was 43%, and the median of ventilator-dependent duration was 22 days (IQR, 12–29). Conclusion: For EGFR mutant lung cancer patients suffering from respiratory failure and undergoing mechanical ventilation, TKI may still be useful, especially in those with EGFR del19 mutation or without shock and DM comorbidity.

show abstract

Section: Introductionmentioning

confidence: 99%

Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation

et al. 2021

View full text Add to dashboard Cite

show abstract

Immune-related adverse events of cancer immunotherapies targeting kinases

Ramos‐Casals¹,

Flores-Chávez²,

Brito-Zerón³

et al. 2022

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Enteral tube administration of oral chemotherapy drugs

Spencer

Menard

Labedz

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective Patients receiving oral chemotherapies face treatment interruptions if they require placement of an enteral tube for nutrition, potentially leading to adverse outcomes in cancer treatment. Enteral tube medication administration can provide a suitable alternative. The purpose of this review is to compile available data that describe enteral tube administration of oral chemotherapy agents. Data sources: A systematic evaluation of all Food and Drug Administration-approved oral chemotherapy agents through 31 July 2019 was conducted. Information on crushing or opening of the tablet or capsule, enteral tube administration, and extemporaneous formulations was compiled from the prescribing information, tertiary resources, and primary literature. Drug manufacturers were contacted for additional information. Data summary: A total of 87 oral chemotherapy agents were evaluated. Of the 87 drugs, 33 agents (37.9%) had information regarding enteral tube administration with only four drugs with nasogastric or gastric tube administration instructions in their prescribing information. The strength of evidence varied from non-peer reviewed data to complete evaluations of efficacy and safety. The majority of chemotherapies (62%) had no available data on enteral tube administration. Conclusions The results of this review suggest that there is limited data surrounding enteral tube administration of most oral chemotherapies, demonstrating the need for more studies to be conducted to provide more guidance to healthcare providers when administration via an enteral tube is needed in their patients.

show abstract

Efficacité de l’erlotinib en réanimation chez les patients présentant un cancer bronchique non à petites cellules avec une mutation de l’EGFR

Cited by 3 publications

References 11 publications

Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation

Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation

Immune-related adverse events of cancer immunotherapies targeting kinases

Enteral tube administration of oral chemotherapy drugs

Contact Info

Product

Resources

About